Artal Group’s Adaptive Biotechnologies ADPT Stock Holding History

Artal Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100,000	Closed	-$4.86M	–	132
2020 Q3	$4.86M	Sell	100,000 -88,000	-47%	-$3.7M	0.12%	100
2020 Q2	$9.1M	Sell	188,000 -12,000	-6%	-$438K	0.25%	74
2020 Q1	$5.56M	Buy	200,000 +50,000	+33%	+$1.39M	0.23%	72
2019 Q4	$4.49M	Hold	150,000	–	–	0.17%	76
2019 Q3	$4.63M	Sell	150,000 -50,000	-25%	-$2.04M	0.19%	74
2019 Q2	$9.66M	Buy	+200,000	New	+$8.86M	0.39%	53

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group's ADPT Position: Q4 2020 in Review

Artal Group sold out of Adaptive Biotechnologies (ADPT) in Q4 2020, closing a stake of 100,000 shares — an estimated $4.86M sold.

Artal Group first reported a position in ADPT in Q2 2019 and held it in 6 quarters. The position peaked at $9.66M in Q2 2019. 250 funds tracked by Wall St. Rank hold ADPT as of Q4 2020.

Artal Group reported no remaining Adaptive Biotechnologies position as of Q4 2020 after selling out during the quarter.
Artal Group sold 100,000 Adaptive Biotechnologies shares in Q4 2020, an estimated $4.86M.
Artal Group first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 6 quarters.
Artal Group's Adaptive Biotechnologies position peaked at $9.66M in Q2 2019.
250 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.